|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
 |
Case ID: 4964 | Drugs / Medical | 12/28/2006
InterMune Inc., a biopharmaceutical company based out of California, has agreed to pay the government $36.9 million to resolve criminal charges and civil liabilities in connection with allegations of illegally promoting Actimmune for treatment of idiopathic pulmonary fibrosis (IPF) or lung scarring, despite not receiving approval for such treatment by the U.S. Food and Drug Administration.
Legal documents state that InterMune's drug Actimmune was approved by the Food and Drug Administration for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. However, from August 2002 until at least January 2003, the government alleges that InterMune promoted Actimmune for the treatment of idiopathic pulmonary fibrosis, for which it was not approved. The government claims that between August 2002 and January 2003, the vast majority of Actimmune sales were for idiopathic pulmonary fibrosis. Attorneys for the government affirm that InterMune's sales force was encouraged to tell doctors that the drug demonstrated a survival benefit for idiopathic pulmonary fibrosis. According to the United States Attorney for the Northern District of California, InterMune will pay the government a total of $36.9 million to resolve allegations under the False Claims Act. It will pay $30.2 million plus interest for costs to Medicare, Medicaid, Veteran's Administration, Defense Department and federal employees' health benefit programs, and $6.6 million to state Medicaid programs. If you or a loved one took Actimmune for idiopathic pulmonary fibrosis, one of our lawyers may be able to assist you. Please call 1-866-467-1400 to speak with one of our lawyers , or click on the link on this page to make a claim. Register your Intermune ComplaintIf you or someone you know has been affected by this case, you may qualify for a money settlement as the result of your financial/economic or other damages that may be awarded either prior to a lawsuit or after the initiation of a lawsuit either currently in progress or filed just for you, possibly a class action lawsuit. Please simply register your complaint by clicking here for Intermune, or click the red "submit" button on this page, and a lawyer will review your Intermune complaint. By submitting your complaint, you are asking lawyers to contact you. You are under no obligation to accept their services and you are free to choose which lawyer you want to work with. Lawyers are usually paid out of the proceeds of the settlement or verdict rendered - the lawyers work on "contingency" by fronting the costs of your lawsuit based on their belief that they will recover a settlement for you. At Lawcash.com, it is our goal to keep you informed about important legal cases, class actions and settlements. Our lawyers offer free legal evaluations in tort cases, class actions, personal injury, and other lawsuits because we are dedicated to helping you resolve your legal complaints. Other Drugs / Medical Cases of Interest A class action has been filed against Tripos, Inc. (Nasdaq: TRPS) and certain of its officers and directors by stockholders who purchased the company's common stock between January 9 and July 1, 2002. Kahn Gauthier Swick, LLC ("Kahn Gauthier") today announced that it filed a class action lawsuit in the United States District Court for the Eastern District of Louisiana on behalf of purchasers of OCA, Inc. ("OCA" or "the Company") (NYSE:OCA) common stock during the period between May 18, 2004 and June 6, 2005 (the "Class Period").
Several class actions have been filed against pharmacy benefit management company Express Scripts, Inc., (Nasdaq:ESRX) and certain of its officers and directors by stockholders who purchased the company's common stock between October 29, 2003, and August 3, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. Several class actions have been filed against medical products and services company Cardinal Health, Inc., (NYSE:CAH) and certain of its officers and directors by stockholders who purchased the company's common stock between October 24, 2000, and June 30, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. A class action lawsuit has been filed in federal court against pharmaceutical giant Novartis Corporation. The cover sheet filed with the complaint indicates that the case alleges discrimination in employment, and seeks damages of one hundred million dollars. The full text of the complaint is not yet accessible and no additional information about the substance of the allegations is available at this time. Classactionamerica.com will monitor this case and provide additional details as soon as they become available. Kahn Gauthier Swick is investigating possible legal actions against the makers of Paxil, Prozac, Zoloft, Lexapro, Celexa, Effexor, and Wellbutrin, respectively, to recover for suicides or homicides--some completed, some only attempted--by patients in the first few days or weeks after they were prescribed one of these drugs. |
IT'S FREE
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.
